Abstract
Cognitive impairment is a core symptom of schizophrenia. It is among the strongest predictors of quality of life and functioning in this population. Although the mechanisms underlying cognitive impairment in schizophrenia are still poorly understood, dopamine receptor blockade by antipsychotics may be a contributing factor. Applying population pharmacokinetic analysis to a dataset from the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial, we recently demonstrated that individuals with schizophrenia with an estimated dopamine D2/3 receptor (D2/3R) occupancy level by antipsychotics of 78% or higher were more cognitively impaired (particularly in attention) than those with lower occupancy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
